Clinical trials: Alopecia
Alopecia
Fractional Non-ablative Laser for the Treatment of Hair Loss
This is a single center, prospective, open label clinical trial with before-after study design. The study is designed to evaluate the feasibility of hair growth in female and male pattern hair loss (androgenic alopecia, telogen…
- Trial name
- NCT04953416
- Testing
- 1565nm non ablative fractional laser
- Where
- Ukraine
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.
Androgenic Alopecia, Hair Loss/Baldness
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss).
- Conditions
- Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
- Trial name
- NCT07637071
- Testing
- Xtressé Hair Growth Gummies
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Alopecia Androgenica
Exosome Treatment and Hair Growth
This study investigates a novel exosome-based plant formulation for treating male pattern baldness (androgenetic alopecia), a condition that affects self-esteem and well-being.
- Trial name
- exosome (NCT06930326)
- Testing
- intradermal exosome, 0.9 % NaCl
- Where
- Malaysia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- COSMEDICIAN AP SDN BHD
Alopecia Areata
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with…
- Trial name
- NCT06340360
- Testing
- Rezpegaldesleukin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 94 people
- Sponsor
- Nektar Therapeutics
Androgenetic Alopecia
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males
The overall purpose of this clinical investigation is to collect data to support a marketing application for over the counter use of the X5 HairLaser with an indication for hair growth.
- Trial name
- NCT02067260
- Testing
- X5 HairLaser
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Spencer Forrest, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451125
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Activated PRP for Treatment of Androgenetic Alopecia
A clinical trial to assess the effects and safety of PRP activated with pulsed electrical fields (PEFA-PRP) compared with unactivated PRP when used to treat AGA.
- Trial name
- NCT05348343
- Testing
- Autologous platelet-rich plasma
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Santiste Medical Inc.
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Alopecia
AVODART® Alopecia Post-marketing Surveillance (PMS)
Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients
- Trial name
- AVODART®PMS (NCT01004809)
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 712 people
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
- Trial name
- NCT04945226
- Testing
- Finasteride 1mg Tablet, IVL3001
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
- Conditions
- Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
- Trial name
- NCT06501924
- Testing
- DA-005, Topical minoxidil 5%, DA-002
- Volunteers
- 516 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Alopecia, Male Pattern Hair Loss
To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
The study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of GT20029 solution.
- Trial name
- NCT06692465
- Testing
- GT20029 Tincture
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Alopecia Areata, Vitiligo
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
- Conditions
- Alopecia Areata, Vitiligo, Atopic Dermatitis, Psoriasis
- Trial name
- Derma-001 (NCT06319781)
- Testing
- Observational
- Where
- 3 sites in Denmark
- Volunteers
- 370 people
- Sponsor
- Blueskin AS
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Alopecia, Androgenetic
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
- Trial name
- NCT05802173
- Testing
- TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Technoderma Medicines Inc.
Androgenetic Alopecia
XVIE to Treat Androgenetic Alopecia (AGA)
This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss).
- Trial name
- NCT07482423
- Testing
- Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Alopecia Areata
A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
This first in human phase 1 study to Study will evaluate safety, tolerability, and pharmacokinetics of Single Ascending dose (SAD), Food effect (FE) and Multiple ascending dose (MAD) of OR-101 Administered Orally in healthy…
- Trial name
- NCT06045624
- Testing
- OR-101 (Single ascending dose), OR-101 (Food effect), OR-101 (Multiple ascending dose)
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ornovi, Inc.
Androgenic Alopecia
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects with Androgenic Alopecia.
- Trial name
- NCT02824380
- Testing
- DA-4001 H, DA-4001 L
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Dong-A ST Co., Ltd.
Alopecia, Androgenetic, Healthy
Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia
Androgenetic alopecia is a chronic pathology affecting approximately 50% of men at 50 years old and is characterized by a progressive miniaturization of the hair follicle leading to a localized baldness.
- Trial name
- NCT06854432
- Testing
- Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique